Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Single-dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Patients With COPD
Verified date | March 2018 |
Source | Sunovion Respiratory Development Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in patients with Chronic Obstructive Pulmonary Disease (COPD). The study was conducted in 12 patients in 2 parts. Part 1 was designed to find the once-a- day GIS dose that produced the highest improvement in lung airflow. Part 2 tested the GIS dose with the highest improvement in lung airflow and a placebo (ie, no drug) delivered by a general purpose nebulizer. The airflow improvements of the same GIS dose were compared between the two nebulizer systems to determine what effect the device had on GIS delivery.
Status | Completed |
Enrollment | 12 |
Est. completion date | July 2009 |
Est. primary completion date | July 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Male and female patients aged 40 through 75 years, inclusive 2. A clinical diagnosis of COPD according to the GOLD guidelines 3. Current smokers or ex-smokers with at least 10 pack-year smoking history (e.g., at least 1 pack/day for 10 years, or 10 packs/day for 1 year) 4. Post-bronchodilator FEV1 40-80% of predicted normal 5. Post-bronchodilator FEV1/FVC ratio < 0.70 6. Improvement in FEV1 >12% (minimum 150 mL) following inhalation of ipratropium bromide 7. Ability to perform reproducible spirometry according to the ATS/ERS guidelines 8. If female and of childbearing potential, must have had a negative pregnancy test and was not lactating at the Screening Visit, and was using one of the following acceptable means of birth control throughout the study: - Post-menopausal for at least two years - Surgically sterile - Oral contraceptives (taken for at least one month prior to the Screening Visit) - Approved implantable or injectable contraceptives (e.g., Norplant®, Depo-Provera® or equivalent) - Barrier methods (e.g., condoms with spermicide) - Intrauterine device (i.e., IUD) - Vasectomy of male partner - Non-heterosexual life style 9. Willing and able to provide written informed consent Exclusion Criteria: 1. Current evidence or recent history of any clinically significant disease (other than COPD) or abnormality in the opinion of the Investigator that would put the patients at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infraction, hypertension, arrhythmia, diabetes, neurological or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities. 2. Recent history of an exacerbation of airway disease within 3 months or need for increased treatments for COPD within 6 weeks prior to the Screening Visit. 3. Regular use of daily oxygen therapy. 4. Use of systemic (e.g., intramuscular or intravenous) steroids within 3 months prior to the Screening Visit 5. Respiratory tract infection within 6 weeks prior to the Screening Visit 6. History of tuberculosis, bronchiectasis or other non-specific pulmonary disease 7. History of urinary retention or bladder neck obstruction type symptoms 8. History of narrow-angle glaucoma 9. Current or recent history (previous 12 months) of excessive use or abuse of alcohol 10. Current evidence or history of abusing legal drugs or the use of illegal drugs or substances 11. History of hypersensitivity or intolerance to aerosol medications 12. Participation in another investigational drug study where drug was received within 30 days prior to the Screening Visit |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sunovion Respiratory Development Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects Who Died | 0-47 days | ||
Primary | Number of Subjects With Treatment Emergent SAEs | AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment.AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition. | 0-47 days | |
Primary | Number of Subjects Who Discontinued Due to AE | AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. | 0-47 days | |
Primary | Percentage of Subjects With Treatment Emergent AEs | AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. | 0-47 days | |
Primary | Number of Subjects With Clinically Significant Abnormal Vital Signs Reported During the Study | Vital signs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study assessment. The clinical significance of each out of normal range vital sign parameter was determined by the investigator during the study. | 30 hrs post dose | |
Primary | Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study | Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study. | day 47 (post studyfollow-up assessment) | |
Primary | Number of Subjects With Clinically Significant ECG Parameters Reported During the Study | ECGs were measured at screening, during the study (pre-dose, and 30 and 60 minutes and 2, 4, 8, 12, 24 and 30 hours post-dose) and at post study follow-up assessment. | 30hr post dose | |
Primary | Number of Subjects With Clinically Significant Abnormal Laboratory Results Reported During the Study | Clinical safety lab parameters were collected at screening and at the post study follow-up assessment. The clinical significance of each out of normal range laboratory parameter was determined by the investigator during the study. | post study follow-up assessment (Day 47) | |
Primary | Number of Subjects With Treatment Emergent AEs | AEs are defined as existing conditions which worsen or events which occur during the course of the clinical trial after treatment. SAEs are AEs that result in the following outcomes: death, are life-threatening, persistent or significant disability/incapacity, congenital anomaly/birth defect, or important medical events that may have been considered a SAE when, based upon appropriate medical judgment, they may have jeopardized the subject and may have required medical or surgical intervention to prevent one of the outcomes listed in the definition. | 0-47 days | |
Secondary | Trough FEV1 (Change From Baseline) | Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. Trough FEV1 was defined as the spirometry value collected at 24 hours post dose within each Treatment Period. | 24hr post dose | |
Secondary | Peak FEV1 (Percent Change) | Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. | 0 to 4hr | |
Secondary | Peak FEV1 (Change From Baseline ) | Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. | 0 to 4hr | |
Secondary | FEV1 AUC0-24 Area Under the FEV1 Over Time Curve (Change From Baseline) | Spirometry measurements were conducted in accordance with the current ATS/ERS 2005 guidelines. | 0 to 24hr post dose | |
Secondary | Cmax Maximum Observed Plasma Concentration | Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr | 0 to 12 hours post dose | |
Secondary | Tmax Time to Maximum Observed Plasma Concentration | Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr | 0 to 12 hours post dose | |
Secondary | AUC0-t Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration | Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr | 0 to 12 hourr post dose | |
Secondary | AUC0-inf Area Under the Plasma Concentration-time Curve From Time Zero to Infinity | Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr | 0 to 12 hours post dose | |
Secondary | t1/2 Plasma Half-life | Pk parameters are calculated from glycopyrrolate plasma concentration analysed from serial blood samples collected between 0 and 12 hr. | 0 to 12 hours post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|